Afraxis, Inc. Announces New Imagedirect (SM) Analysis Service
SAN DIEGO, March 9, 2017 /PRNewswire/ -- Afraxis Inc, a leader in quantitative biological imaging, is very pleased to announce its new ImageDirectSM service, the world's first upload service for quantitative analysis of 3D biological images. ImageDirectSM offers a platform for AI-assisted, expert crowd-sourced human analysis with initial iteration optimized for 'Z-stack' images of neural tissue acquired by confocal scanning laser microscopy.
Academic research labs and drug development teams can now submit images directly to Afraxis at http://www.afraxis.com/client-upload-general/ to a persistent image container object on Afraxis' secure cloud, define the target features, type of analysis, and the desired report format. Afraxis will provide timely responses on cost and turn-around time for a full quantitation of any submitted image deck.
Our expert crowd-sourced analyst team then provides unbiased measurement and full analytics with a one-week or shorter turn-around time for most studies.
Afraxis also develops and validates new quantitation methodologies, novel feature identification procedures, and analytical frameworks customized to given experimental design, purpose and aims.
About Afraxis Inc
Afraxis Inc is a contract research organization (CRO) specializing in:
•CNS preclinical efficacy evaluations (in vivo & in vitro)
•Neurotoxicity evaluations
•Structure-Efficacy Relationship (SER)-driven medicinal chemistry
Afraxis' patented ESP (Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations. The ESP process incorporates specialized labeling of individual neurons; high-resolution imaging; rapid high-detail morphometry of individual cells, processes, and synapses; and powerful statistical methods and analytical displays tailored for efficient interpretation of large data sets.
More information at www.afraxis.com, or contact Afraxis Inc at info@afraxis.com
Media Contact:
Mehrak Hamzeh
mhamzeh@afraxis.com
858.997.9135
Academic research labs and drug development teams can now submit images directly to Afraxis at http://www.afraxis.com/client-upload-general/ to a persistent image container object on Afraxis' secure cloud, define the target features, type of analysis, and the desired report format. Afraxis will provide timely responses on cost and turn-around time for a full quantitation of any submitted image deck.
Our expert crowd-sourced analyst team then provides unbiased measurement and full analytics with a one-week or shorter turn-around time for most studies.
Afraxis also develops and validates new quantitation methodologies, novel feature identification procedures, and analytical frameworks customized to given experimental design, purpose and aims.
About Afraxis Inc
Afraxis Inc is a contract research organization (CRO) specializing in:
•CNS preclinical efficacy evaluations (in vivo & in vitro)
•Neurotoxicity evaluations
•Structure-Efficacy Relationship (SER)-driven medicinal chemistry
Afraxis' patented ESP (Enhanced Spine Profiling) technology produces rapid, high-information read-outs of synaptic networks from in-vivo/in-vitro/ex-vivo preparations. The ESP process incorporates specialized labeling of individual neurons; high-resolution imaging; rapid high-detail morphometry of individual cells, processes, and synapses; and powerful statistical methods and analytical displays tailored for efficient interpretation of large data sets.
More information at www.afraxis.com, or contact Afraxis Inc at info@afraxis.com
Media Contact:
Mehrak Hamzeh
mhamzeh@afraxis.com
858.997.9135